MFAM
NBIX icon

Motley Fool Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Motley Fool Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Buy
2,540
+688
+37% +$102K 0.02% 194
2026
Q1 		$244K Buy
1,852
+159
+9% +$21.1K 0.01% 225
2025
Q4 		$240K Buy
1,693
+78
+5% +$11.3K 0.01% 229
2025
Q3 		$227K Sell
1,615
-1,052
-39% -$143K 0.01% 229
2025
Q2 		$335K Buy
2,667
+209
+9% +$24K 0.02% 193
2025
Q1 		$272K Buy
2,458
+209
+9% +$26.5K 0.02% 203
2024
Q4 		$307K Buy
2,249
+220
+11% +$27.2K 0.02% 194
2024
Q3 		$232K Sell
2,029
-24
-1% -$3.29K 0.01% 199
2024
Q2 		$288K Sell
2,053
-14
-0.7% -$1.92K 0.02% 185
2024
Q1 		$285K Buy
2,067
+197
+11% +$26.9K 0.02% 201
2023
Q4 		$246K Sell
1,870
-168
-8% -$19.3K 0.02% 201
2023
Q3 		$229K Buy
+2,038
New +$215K 0.02% 204
2023
Q1 		– Sell
-1,721
Closed -$206K – 172
2022
Q4 		$206K Buy
+1,721
New +$202K 0.02% 207
2022
Q1 		– Sell
-44
Closed -$4K – 284
2021
Q4 		$4K Buy
+44
New +$4.05K ﹤0.01% 244

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Motley Fool Asset Management's NBIX Position: Q2 2026 in Review

Motley Fool Asset Management increased its Neurocrine Biosciences (NBIX) stake by 37% in Q2 2026, buying an estimated $102K and bringing the position to 2,540 shares worth $428K. The position accounts for 0.02% of the portfolio, ranked #194.

Motley Fool Asset Management first reported a position in NBIX in Q4 2021 and has held it in 14 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Motley Fool Asset Management held 2,540 shares of Neurocrine Biosciences worth $428K as of Q2 2026.
  • Motley Fool Asset Management bought 688 Neurocrine Biosciences shares in Q2 2026, an estimated $102K.
  • Neurocrine Biosciences made up 0.02% of Motley Fool Asset Management's portfolio in Q2 2026, its #194 holding.
  • Motley Fool Asset Management first reported a position in Neurocrine Biosciences in Q4 2021 and has held it in 14 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Motley Fool Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.